In large-scale genomic studies of meningioma, higher grade (WHO grade II and III) meningioma were in some studies exclusively related to pathogenic variants in NF2, associated with mutations in the TERT promoter, and deletion of 1p and CDKN2A [30, 34]. This evidence concerns the gene CDKN2A and meningioma.